AKRO•benzinga•May 12, 2025 at 11:20 AM

Akero Therapeutics Q1 2025 EPS $(0.90) Beats $(0.99) Estimate, Cash, Cash Equivalents, And Short- And Long-term Marketable Securities As Of March 31, 2025, Were $1.128B, Will Be Sufficient To Fund Its Current Operating Plan Into 2028

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 12, 2025 by benzinga